About: Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold
Creator	Prieschl-Grassauer, Eva Eccles, Ron Grassauer, Andreas Jawad, Martez Meier, Christiane Weinmüllner, Regina
Source	Medline; PMC
abstract	BACKGROUND: The common cold, the most prevalent contagious viral disease in humans still lacks a safe and effective antiviral treatment. Iota-Carrageenan is broadly active against respiratory viruses in-vitro and has an excellent safety profile. This study investigated the efficacy and safety of an Iota-Carrageenan nasal spray in patients with common cold symptoms. METHODS: In a randomized, double-blind, placebo-controlled exploratory trial, 35 human subjects suffering from early symptoms of common cold received Iota-Carrageenan (0.12%) in a saline solution three times daily for 4 days, compared to placebo. RESULTS: Administration of Iota-Carrageenan nasal spray reduced the symptoms of common cold (p = 0.046) and the viral load in nasal lavages (p = 0.009) in patients with early symptoms of common cold. Pro-inflammatory mediators FGF-2, Fractalkine, GRO, G-CSF, IL-8, IL-1α, IP-10, IL-10, and IFN-α2 were reduced in the Iota-Carrageenan group. CONCLUSIONS: Iota-Carrageenan nasal spray appears to be a promising treatment for safe and effective treatment of early symptoms of common cold. Larger trials are indicated to confirm the results.
has issue date	2010-08-10(xsd:dateTime)
bibo:doi	10.1186/1465-9921-11-108
bibo:pmid	20696083
has license	cc-by
sha1sum (hex)	1552cf77b6385950e197c67c2ed55ed6e1879ced
schema:url	https://doi.org/10.1186/1465-9921-11-108
resource representing a document's title	Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold
has PubMed Central identifier	PMC2923116
has PubMed identifier	20696083
schema:publication	Respir Res
resource representing a document's body	covid:1552cf77b6385950e197c67c2ed55ed6e1879ced#body_text
is schema:about of	named entity 'effective' named entity 'double-blind' named entity 'suffering' named entity 'symptoms' covid:arg/1552cf77b6385950e197c67c2ed55ed6e1879ced named entity 'prevalent' named entity 'study' named entity 'viral disease' named entity 'safe and effective' named entity 'nasal spray' named entity 'Iota-Carrageenan' named entity 'in-vitro' named entity 'common cold' named entity 'Perchtoldsdorf' named entity 'sore throat' named entity 'cytokines' named entity 'blocked nose' named entity 'Iota-Carrageenan' named entity 'statistical difference' named entity 'Iota-Carrageenan' named entity 'blocked nose' named entity 'respiratory tract' named entity 'runny nose' named entity 'placebo' named entity 'IL-6' named entity 'IL-12' named entity 'viruses' named entity 'clinical trials' named entity 'common cold' named entity 'virus' named entity 'SSS' named entity 'detection limit' named entity 'Iota-Carrageenan' named entity 'sneezing' named entity 'nasal bleeding' named entity 'common cold' named entity 'clinical trials' named entity 'IL-4' named entity 'Iota-Carrageenan' named entity 'HRV' named entity 'Rhodophyceae' named entity 'Iota-Carrageenan' named entity 'upper respiratory tract infection' named entity 'nasal cavity' named entity 'muscle ache' named entity 'headache' named entity 'indirect costs' named entity 'migraine' named entity 'molecule' named entity 'symptom' named entity 'nasal obstruction' named entity 'Cytokine' named entity 'nasal spray' named entity 'placebo' named entity 'ibuprofen' named entity 'sore throat' named entity 'IL-1α' named entity 'viral transmission' named entity 'Iota-Carrageenan' named entity 'nasal spray' named entity '3, 4' named entity 'Iota-Carrageenan' named entity 'nasal spray' named entity 'IL-1β' named entity 'standard deviation' named entity 'viral load' named entity 'symptom' named entity 'safe and effective' named entity 'infection' named entity 'VEGF' named entity 'Iota-Carrageenan' named entity 'placebo-controlled' named entity 'primary endpoint' named entity 'Iota-Carrageenan' named entity 'Iota-Carrageenan' named entity 'cytokine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software